Biosplice Therapeutics Stock
Tissue-Level Regeneration
Sign up today and learn more about Biosplice Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Biosplice Therapeutics Stock
Samumed is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
Investors
aMoon Fund
Esas Ventures
Eventide Asset Management
Polar Light Ventures
Sands Capital Management
Starling group
Symbiosis Group
Vickers Venture Partners
Funding History
| February 2021 | $60.0M |
|---|---|
| March 2021 | $60.0M |
Management
Chief Executive Officer
Samikoglu Cevdet
Chief Financial Officer
Horsley Erich
Press
bioworld - May, 6 2023
Biosplice Therapeutics discovers new DYRK1A inhibitorsfiercebiotech - Feb, 9 2022
After reaching a high with $12B valuation, Biosplice lays off staff and axes baldness programtinyurl - Jun, 22 2021
Dave Johnson Joins Biosplice Therapeutics Board of Directorstechstartups - Nov, 20 2020
Unicorn startup companies 2020: List of top 500 unicorn startups with valuation of $1 Billion+Globe Newswire - Jun, 1 2020
Michael White, Ph.D. joins Samumed as Chief Scientific Officerxconomy - Jun, 1 2020
Samumed Taps Pfizer’s Michael White as Its Chief Scientific OfficerIntrado - Oct, 2 2019
Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumorsnanalyze - Aug, 23 2019
The Top 10 Companies Working to Increase Longevityfiercebiotech - Aug, 16 2019
In conversation with Samumed CEO Osman Kibar: Drugging Wnt, restoring youth and unconventional capitalIntrado - Jul, 18 2019
Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimer’s Diseaseventurebeat - May, 16 2019
Fastest Growing Companies in California Cities awarded by Growjo: San Francisco, Silicon Valley, Los Angeles, San Diego, etc.fiercebiotech - May, 15 2019
2. SamumedIntrado - May, 2 2019
Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee OsteoarthritisGlobe Newswire - Feb, 28 2019
Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritisnanalyze - Nov, 3 2018
When Will There Ever Be a Cure for Baldness?EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
